TY - JOUR
AU1 - Harigai, Masayoshi
AU2 - Koike, Ryuji
AU3 - Miyasaka, Nobuyuki
AB - To the Editor: Infliximab, a monoclonal antibody against tumor necrosis factor α (TNF-α), is used in Japan for the treatment of patients with active rheumatoid arthritis that is resistant to methotrexate.1 Methotrexate is used only for patients who do not have a response to or cannot tolerate other disease-modifying antirheumatic drugs, such as sulfasalazine. Infliximab is not used as primary therapy for rheumatoid arthritis in Japan. Strict postmarketing surveillance of infliximab and etanercept, a drug that blocks the action of TNF, revealed incidences of pneumocystis pneumonia in Japanese patients with rheumatoid arthritis that were higher (0.4% and 0.2%, respectively) than . . .
TI - Pneumocystis Pneumonia Associated with Infliximab in Japan
JF - The New England Journal of Medicine
DO - 10.1056/NEJMc070728
DA - 2007-11-01
UR - https://www.deepdyve.com/lp/the-new-england-journal-of-medicine/pneumocystis-pneumonia-associated-with-infliximab-in-japan-PHy4k7lr0L
SP - 1874
EP - 1876
VL - 357
IS - 18
DP - DeepDyve
ER -